Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes.


Abstract

Deep mutational scanning has emerged as a promising tool for mapping sequence-activity relationships in proteins, ribonucleic acid and deoxyribonucleic acid. In this approach, diverse variants of a sequence of interest are first ranked according to their activities in a relevant assay, and this ranking is then used to infer the shape of the fitness landscape around the wild-type sequence. Little is currently known, however, about the degree to which such fitness landscapes are dependent on the specific assay conditions from which they are inferred. To explore this issue, we performed comprehensive single-substitution mutational scanning of APH(3')II, a Tn5 transposon-derived kinase that confers resistance to aminoglycoside antibiotics, in Escherichia coli under selection with each of six structurally diverse antibiotics at a range of inhibitory concentrations. We found that the resulting local fitness landscapes showed significant dependence on both antibiotic structure and concentration, and that this dependence can be exploited to guide protein engineering. Specifically, we found that differential analysis of fitness landscapes allowed us to generate synthetic APH(3')II variants with orthogonal substrate specificities.

Submission Details

ID: XKe3Fnvw

Submitter: Shu-Ching Ou

Submission Date: Feb. 11, 2019, 4:25 p.m.

Version: 1

Publication Details
Melnikov A;Rogov P;Wang L;Gnirke A;Mikkelsen TS,Nucleic Acids Res (2014) Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. PMID:24914046
Additional Information

WT amino acid (AA) counts/differences are calculated as the mean values of WT counts/differences at all positions. Refer to the assay detail for the definition of amino acid differences. For assay naming: S=Selection round 1, 2, 3, or 4. D=Drug and dilution, eg. Kan12 refers to Kanamycin at 1:2 WT MIC. L=Input library 1 or 2. Estimated 1:1 WT MICs: 225 μg/mL for kanamycin (Kan), 2500 μg/mL for ribostamycin (Ribo), 5 μg/mL for G418, 10 μg/mL for amikacin (Ami), 40 μg/mL for neomycin (Neo) and 320 μg/mL for paromomycin (Paro).

Study Summary

Number of data points 571938
Proteins Aminoglycoside 3'-phosphotransferase
Unique complexes 35119
Assays/Quantities/Protocols Experimental Assay: AA counts: Input L(ibrary)=1 ; Experimental Assay: AA counts: S=3, Dilution=1:2 WT MIC, L=1 ; Experimental Assay: AA counts: S=3, Dilution=1:1 WT MIC, L=1 ; Experimental Assay: AA counts: S=2, Dilution=1:2 WT MIC, L=2 ; Experimental Assay: AA counts: S=2, Dilution=1:1 WT MIC, L=2 ; Experimental Assay: AA counts: S=1, Dilution=1:2 WT MIC, L=1 ; Experimental Assay: AA counts: S=1, Dilution=1:1 WT MIC, L=1 ; Experimental Assay: AA counts: Input L(ibrary)=2 ; Experimental Assay: AA counts: S=4, Dilution=1:8 WT MIC, L=2 ; Experimental Assay: AA counts: S=4, Dilution=1:4 WT MIC, L=2 ; Experimental Assay: AA counts: S=3, Dilution=1:8 WT MIC, L=1 ; Experimental Assay: AA counts: S=3, Dilution=1:4 WT MIC, L=1 ; Experimental Assay: AA counts: S=2, Dilution=1:32 WT MIC, L=2 ; Experimental Assay: AA counts: S=2, Dilution=1:16 WT MIC, L=2 ; Experimental Assay: AA counts: S=2, Dilution=1:8 WT MIC, L=2 ; Experimental Assay: AA counts: S=2, Dilution=1:4 WT MIC, L=2 ; Experimental Assay: AA counts: S=1, Dilution=1:32 WT MIC, L=1 ; Experimental Assay: AA counts: S=1, Dilution=1:16 WT MIC, L=1 ; Experimental Assay: AA counts: S=1, Dilution=1:8 WT MIC, L=1 ; Experimental Assay: AA counts: S=1, Dilution=1:4 WT MIC, L=1 ; Derived Quantity: AA diff: S=3, Dilution=1:2 WT MIC, L=1 ; Derived Quantity: AA diff: S=3, Dilution=1:1 WT MIC, L=1 ; Derived Quantity: AA diff: S=2, Dilution=1:2 WT MIC, L=2 ; Derived Quantity: AA diff: S=2, Dilution=1:1 WT MIC, L=2 ; Derived Quantity: AA diff: S=1, Dilution=1:2 WT MIC, L=1 ; Derived Quantity: AA diff: S=1, Dilution=1:1 WT MIC, L=1 ; Derived Quantity: AA diff: S=4, Dilution=1:8 WT MIC, L=2 ; Derived Quantity: AA diff: S=4, Dilution=1:4 WT MIC, L=2 ; Derived Quantity: AA diff: S=3, Dilution=1:8 WT MIC, L=1 ; Derived Quantity: AA diff: S=3, Dilution=1:4 WT MIC, L=1 ; Derived Quantity: AA diff: S=2, Dilution=1:32 WT MIC, L=2 ; Derived Quantity: AA diff: S=2, Dilution=1:16 WT MIC, L=2 ; Derived Quantity: AA diff: S=2, Dilution=1:8 WT MIC, L=2 ; Derived Quantity: AA diff: S=2, Dilution=1:4 WT MIC, L=2 ; Derived Quantity: AA diff: S=1, Dilution=1:32 WT MIC, L=1 ; Derived Quantity: AA diff: S=1, Dilution=1:16 WT MIC, L=1 ; Derived Quantity: AA diff: S=1, Dilution=1:8 WT MIC, L=1 ; Derived Quantity: AA diff: S=1, Dilution=1:4 WT MIC, L=1
Libraries Variants for APH-Ribo ; Variants for APH-Kan ; Variants for APH-G418 ; Variants for APH-Paro ; Variants for APH-Neo ; Variants for APH-Ami ; Variants for APH

Structure view and single mutant data analysis

Study data

No weblogo for data of varying length.
Colors: D E R H K S T N Q A V I L M F Y W C G P
 

Data Distribution

Studies with similar sequences (approximate matches)

Correlation with other assays (exact sequence matches)


Relevant UniProtKB Entries

Percent Identity Matching Chains Protein Accession Entry Name
200.0 A,B Aminoglycoside 3'-phosphotransferase P00552 KKA2_KLEPN